More tools:Markets·Screener·Research Chat

Bristol-Myers Squibb Co. (BMY) Financial Statements

Bristol-Myers Squibb Co.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S8N8J6
XNYS · usd
56.95▼ 2.39 (-4.03%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA—
Financial Highlights
Revenue (TTM)$48.5B
Net Income (TTM)$7.3B
EBITDA—
Diluted EPS (TTM)
EBITDA Margin—
Net Debt
Trading Information
Previous Close59.34
Day's Range56.78 – 59.14
52-Week Range42.52 – 62.89
Volume13.56M
Avg Volume12.45M
Share Statistics
Shares Outstanding2.0B
Employees32.5K
ExchangeXNYS
Listed1952-06-23

Key questions about Bristol-Myers Squibb Co. (BMY)

What is Bristol-Myers Squibb Co.'s Market Cap?
Bristol-Myers Squibb Co.'s Market Cap is $116.3B, based on as-reported figures from SEC (XBRL) filings.
What is Bristol-Myers Squibb Co.'s Enterprise Value?
Bristol-Myers Squibb Co.'s Enterprise Value is $158.1B, based on as-reported figures from SEC (XBRL) filings.
What is Bristol-Myers Squibb Co.'s Trailing P/E?
Bristol-Myers Squibb Co.'s Trailing P/E is 16.0×, based on as-reported figures from SEC (XBRL) filings.
What is Bristol-Myers Squibb Co.'s Price / Sales?
Bristol-Myers Squibb Co.'s Price / Sales is 2.4×, based on as-reported figures from SEC (XBRL) filings.
What is Bristol-Myers Squibb Co.'s EV / Revenue?
Bristol-Myers Squibb Co.'s EV / Revenue is 3.3×, based on as-reported figures from SEC (XBRL) filings.
What is Bristol-Myers Squibb Co.'s Revenue (TTM)?
Bristol-Myers Squibb Co.'s Revenue (TTM) is $48.5B, based on as-reported figures from SEC (XBRL) filings.
What is Bristol-Myers Squibb Co.'s Net Income (TTM)?
Bristol-Myers Squibb Co.'s Net Income (TTM) is $7.3B, based on as-reported figures from SEC (XBRL) filings.
What is Bristol-Myers Squibb Co.'s Diluted EPS (TTM)?
Bristol-Myers Squibb Co.'s Diluted EPS (TTM) is 3.56, based on as-reported figures from SEC (XBRL) filings.
What is Bristol-Myers Squibb Co.'s Net Debt?
Bristol-Myers Squibb Co.'s Net Debt is $36.9B, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Net product sales
Alliance and other revenues———
Total Revenues
YoY growth+2.6%+1.3%+2.8%+0.6%
Cost of products sold (a)
Selling, general and administrative
Research and development
Acquired IPRD
Amortization of acquired intangible assets
Other (income)/expense, net
Total Expenses
% of revenue71.8%88.2%74.5%85.5%
Income (loss) before income taxes
Income tax expense (benefit)
Net earnings/(loss)
% of revenue23.3%8.7%18.0%10.7%
Noncontrolling interest
Net earnings/(loss) attributable to BMS
% of revenue23.3%8.7%18.0%10.7%
Earnings/(Loss) per common share:
Basic
Diluted